Biotricity Files FDA 510(k) For Expanded Use Of Its Biotres Cardiac Monitoring Device

Biotricity Inc BTCY has announced 510(k) submission to the FDA for a new form factor of its Biotres Cardiac Monitoring Device, a three-lead device for ECG and arrhythmia monitoring that is intended for lower-risk patients.
Dr. Waqaas Al-Siddiq, Biotricity Founder and CEO, commented, "We believe this variation of Biotres is an important step to having an expanded product portfolio with maximum variety for the $5B holter monitoring market."
Biotres offers the following feature set:
- A wearable holter patch device that can provide continuous 3-channel recording of ECG (heart) data. All other known holter patch devices are 1 channel or 2 channels.
- It can be worn continuously for 48 hours before needing to be charged for 1 hour.
- Utilizes Bluetooth technology to offload data, reducing the time for diagnoses.
Price Action: BTCY shares are up 10.70% at $0.80 on the last check Monday.